CNBC's Meg Tirrell reports on the abrupt departure of Alexion Pharmaceuticals' CEO and CFO.
TORONTO, Dec 12- German healthcare group Bayer said on Monday it has set up a joint venture with U.S. life sciences venture capital firm Versant Ventures to invest $225 million in a stem cell therapy firm based in Toronto. The venture, BlueRock Therapeutics, is expected to initially employ 30 to 40 people in Toronto, and 70 to 80 people worldwide.
Lonza, the Swiss pharmaceutical manufacturer, is reportedly in talks to purchase Capsugel, a capsule product maker.
Kevin Lobo, Stryker chairman & CEO, talks about some of the company's newest technology in hard tissue robotics and why reform is needed in Obamacare.
Short-seller Andrew Left, Citron Research, discusses his tweet directing Donald Trump's attention towards Express Scripts, and his other shorts in the pharmaceutical space.
Short-seller Andrew Left, Citron Research, explains why Express Scripts is the "Philidor of the pharma industry," referring to Philidor Rx Services' alleged misconduct with Valeant Pharmaceuticals.
Shares of Express Scripts plunge following short-seller Andrew Left's series of tweets taking aim at the company. CNBC's Meg Tirrell reports.
Citron Research tweeted that Express Scripts is "Philidor of the pharma industry," referring to Philidor Rx Services' alleged misconduct.
Jeremy Levin, Ovid Therapeutics CEO, discusses Donald Trump's opposition towards current drug prices, and his outlook on biotech industry.
Les Funtleyder, ESquared Asset Management, weighs in on Donald Trump's attack against drug prices, and the healthcare sector.
CNBC's Meg Tirrell reports on who may be leading the FDA under a Trump presidency.
Chris Meekins, FBR research analyst, discusses three reasons to ignore Donald Trump's comments against the current drug prices.
CNBC's Meg Tirrell reports on which names in biotech were hit hardest last year by Hillary Clinton's tweet calling price gouging "outrageous."
The drug is for the treatment of moderate to severe menapause symptoms like hot flashes and night sweats.
CNBC's Martin Soong reports on the growth potential of the pharmaceutical industry in India, the largest generic drug producer in the world.
Shares of TherapeuticsMD jump on positive drug trial results, CNBC's Seema Mody reports. Paul Hickey, Bespoke Investment Group, and CNBC's Mike Santoli weigh in.
David Schenkein, Agios CEO, speaks to CNBC's Meg Tirrell about his company's pyruvate kinase deficiency drug, stock performance and innovation.
CNBC's Meg Tirrell discusses big movers in biotech, including Kite Pharmaceuticals and Bluebird Bio.
Shares of Eli Lilly gains momentum on news of an FDA drug approval. CNBC's Seema Mody reports.
Kara Swisher, Recode executive editor, shares her take on the Theranos board, calling it "the most unusual board in Silicon Valley."